Educational guide
Teriparatide Dosage Protocol - Peptide Dosages
Teriparatide (10 mg) Dosage Protocol Recombinant parathyroid hormone fragment PTH(1–34) — the approved bone-building drug Forteo. Clinically dosed in micrograms per day, not milligrams. Research-use-only reference; not medical advice and not a dosing recommend
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Teriparatide (10 mg) Dosage Protocol
Recombinant parathyroid hormone fragment PTH(1–34) — the approved bone-building drug Forteo. Clinically dosed in micrograms per day, not milligrams. Research-use-only reference; not medical advice and not a dosing recommendation.
Why Teriparatide draws research interest
These are the directions researchers and the peptide community most often explore Teriparatide for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
The dose is in micrograms — this is the whole safety story
Teriparatide is one of the most potent hormones used in medicine, and it is dosed accordingly: 20 micrograms once a day. A milligram is a thousand micrograms, so a single 10 mg vial contains roughly 500 clinical daily doses. Reconstituted to a typical 5 mg/mL, the 20 mcg clinical amount works out to four thousandths of a millilitre — well under half of one unit on an insulin syringe, a volume no one can measure by eye. The approved product sidesteps this entirely by shipping as a fixed-dose pre-filled pen. The mismatch between a milligram vial and a microgram drug is the single most important thing to understand here, and it is exactly why this page gives no self-dosing instructions.
Pulse versus plateau: the same hormone can build or destroy bone
What makes PTH biology fascinating is that the effect flips depending on how the hormone is delivered. A brief once-daily spike of PTH(1–34) tips the balance toward osteoblasts and net bone formation. Chronically high PTH — as in an overactive parathyroid gland — does the reverse, activating osteoclasts and stripping bone. So teriparatide is anabolic only because it is given as a short daily pulse; get the exposure pattern wrong and the same molecule becomes catabolic. This is a textbook example of why timing and pharmacokinetics, not just the peptide sequence, determine what a hormone does.
The osteosarcoma story, told honestly
Early rat studies found dose- and duration-dependent bone tumors, including osteosarcoma, which led the original US label to carry a boxed warning and a two-year lifetime treatment limit. Two things then happened over nearly two decades of real-world use: a 15-year US post-marketing surveillance study found the osteosarcoma rate in treated patients was no higher than the background population rate, and a large patient registry identified zero cases. On that accumulated human evidence, the FDA removed the boxed warning and the two-year limit in 2020. The honest reading is neither “it causes cancer” nor “it is risk-free” — it is that a real rodent signal was investigated for years and not borne out in humans, while bone metastases, prior skeletal radiation and Paget’s disease remain genuine contraindications.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Mix & measure Teriparatide · 10 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
A parathyroid-hormone fragment that, given as a once-daily pulse, preferentially stimulates bone-building osteoblasts over bone-resorbing osteoclasts, so intermittent exposure builds bone. The exact opposite pattern — continuously elevated PTH — drives bone breakdown, which is why the timing of exposure, not just the molecule, defines the effect.
An FDA-approved anabolic osteoporosis medicine (Forteo) dosed at 20 mcg subcutaneously once daily from a pre-filled pen. It is a genuine drug with strong trial evidence, but that evidence applies to the approved microgram dose and device, not to a milligram-scale research vial reconstituted at home.
The pivotal randomized trial in postmenopausal women with prior vertebral fractures showed large reductions in new vertebral and non-vertebral fractures and gains in spine and hip bone density. Rat studies produced dose- and duration-dependent bone tumors; long-term human surveillance has not found an increased osteosarcoma rate.
Quickstart Highlights
Teriparatide is recombinant human parathyroid hormone (1–34) — the biologically active amino-terminal fragment of the 84-amino-acid hormone PTH, produced in E. coli. It is the active ingredient in Forteo (and its biosimilars), an FDA-approved anabolic (bone-building) treatment for osteoporosis. Unlike almost every other compound catalogued on this site, teriparatide is a fully approved medicine with large randomized-trial evidence[1].
This page is an educational reference explaining what teriparatide is, the single most important fact about how it is dosed, and what the research actually shows. It is not medical advice and not a protocol to self-administer the peptide. The one point that matters above all others: teriparatide is dosed clinically in micrograms (mcg) — the approved dose is 20 mcg once daily[1]. A “10 mg” research vial therefore contains roughly 500 times a single clinical daily dose. Confusing milligrams for micrograms with this hormone is a serious and dangerous error.
The PTH(1–34) fragment of parathyroid hormone — an FDA-approved anabolic osteoporosis drug (Forteo) that builds new bone when given once daily[1].
Clinically 20 mcg/day — micrograms, not milligrams. A 10 mg vial holds ~500 daily clinical doses. The approved product is a pre-filled pen, not a reconstituted vial.
FDA-approved (2002) for osteoporosis at high fracture risk. A grey-market “research vial” is not the approved pen and is not quality-assured.
Robust human RCT data for the approved drug — it cut vertebral and non-vertebral fractures in a pivotal 1,637-woman trial[1]. That evidence belongs to the pen at 20 mcg/day, not to milligram self-dosing.